Stately Bio Raises $12M Seed to Develop Next Generation Regenerative Medicines with ML-Powered Cellular Imaging Platform

Stately Bio 获得 1200 万美元种子轮融资，用于通过机器学习驱动的细胞成像平台开发下一代再生药物。

The company’s patented technology platform produces liver cells with 10x better function than state of the art technologies

该公司的专利技术平台生产的肝细胞功能比现有技术高出10倍。

PALO ALTO, Calif., May 2, 2025-- Stately Bio, a startup developing cell therapies using an ML-powered live-cell imaging platform, today announced $12 million in seed funding led by AIX Ventures, with participation from Dimension Capital, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui Global Investment, BoxOne Ventures, Axial VC, Jeff Dean (Chief Scientist at Google DeepMind), Jeremy Wertheimer (co-founder of ITA Software), and Tom Berry (co-founder of Carbon Health).

加利福尼亚州帕洛阿尔托，2025年5月2日——Stately Bio是一家利用机器学习驱动的活细胞成像平台开发细胞疗法的初创公司，今天宣布获得了1200万美元的种子轮融资。本轮融资由AIX Ventures领投，Dimension Capital、Foothill Ventures、Village Global、Caffeinated Capital、三井全球投资、BoxOne Ventures、Axial VC、Jeff Dean（Google DeepMind首席科学家）、Jeremy Wertheimer（ITA Software联合创始人）和Tom Berry（Carbon Health联合创始人）参与投资。

The company will use the new funding to scale its platform technology and mature its internal pipeline of stem cell-derived therapeutics..

公司将利用新的资金扩大其平台技术，并完善其内部的干细胞衍生疗法管道。

Biologists’ Problem: Measuring Cells Without Killing Them

生物学家的问题：在不杀死细胞的情况下测量它们

A major bottleneck in the development and production of cell therapies is the reliance on destructive approaches to understand cell state. For example, identifying a cell’s differentiation state typically involves breaking open the cell to measure the presence or absence of specific molecules inside it – a process that is slow, expensive, and lethal to the cell.

细胞疗法的开发和生产中的一个主要瓶颈是依赖于破坏性方法来了解细胞状态。例如，确定细胞的分化状态通常涉及将细胞裂解以测量其中特定分子的存在或缺失——这一过程缓慢、昂贵且对细胞具有致命性。

The fact that these measurements can only be taken once per cell makes it extremely difficult to study, monitor, and control how cells change over time. As a result, critical questions, like how to guide stem cells to mature into the right type of tissue cell, often cannot be answered. This gap has hampered the development of cell therapies and regenerative medicine for decades..

这些测量每个细胞只能进行一次，这一事实使得研究、监测和控制细胞随时间的变化变得极其困难。因此，一些关键问题，比如如何引导干细胞成熟为正确类型的组织细胞，常常无法得到解答。这一差距阻碍了细胞疗法和再生医学的发展长达数十年。

“Stately Bio is fundamentally reshaping our understanding of cell therapies by decoding living cell states in real-time, all without invasive methods,” said Krish Ramadurai, partner at AIX Ventures. “This revolutionary approach addresses a critical bottleneck that has long limited breakthroughs in regenerative medicine, unlocking faster development of safer, more effective cell-based treatments.

“Stately Bio 正在通过实时解码活细胞状态，从根本上重塑我们对细胞疗法的理解，且无需采用侵入性方法，”AIX Ventures 合伙人 Krish Ramadurai 表示。“这一革命性的方法解决了一个长期以来限制再生医学突破的关键瓶颈，加速了更安全、更有效的细胞治疗的发展。”

We’re thrilled to support Frank and his exceptional team as they pioneer the next era of cellular medicine for millions of patients.”.

我们非常高兴能够支持弗兰克及其卓越的团队，因为他们正在为数百万患者开创细胞医学的新时代。

Stately Bio’s Solution: Live-Cell Imaging to Enable Better Cell Therapies

Stately Bio的解决方案：活细胞成像助力更好的细胞疗法

Stately Bio’s technology removes the need to choose between measuring cells and keeping them alive. The company’s ML-driven imaging platform identifies and monitors cells in real time using only label-free, live-cell compatible imaging, with no need for fluorescent tags or genetic modification. By applying advanced machine learning, Stately Bio’s technology can quantify diverse cell types, track differentiation progress, optimize protocols, and even forecast manufacturing outcomes, all in real time without ever touching or harming the cells.

Stately Bio的技术消除了在测量细胞和保持它们存活之间做出选择的必要。该公司基于机器学习的成像平台仅使用无标记、活细胞兼容成像来实时识别和监测细胞，无需荧光标记或基因改造。通过应用先进的机器学习，Stately Bio的技术可以量化不同类型的细胞、追踪分化进程、优化实验方案，甚至预测生产结果，所有这些都在不接触或损害细胞的情况下实时完成。

For biopharma companies, these real-time insights translate into faster process development cycles and better control over quality and consistency, ensuring each run meets the purity and functionality needed for patients..

对于生物制药公司而言，这些实时洞察信息可转化为更快速的工艺开发周期，并更好地控制质量和一致性，确保每次运行都能满足患者所需的纯度和功能。

On the discovery side, Stately Bio has deployed its technology platform to improve the differentiation of stem cells into mature cells of high therapeutic value, starting with an industry-leading liver cell program. Compared to the state of the art, Stately Bio’s liver cells show 3x-10x improvement across a panel of metabolic assays of key liver functions.

在发现方面，Stately Bio已经部署了其技术平台，以改善干细胞分化为高治疗价值的成熟细胞，首先是一个行业领先的肝细胞项目。与现有技术相比，Stately Bio的肝细胞在关键肝脏功能的一系列代谢检测中显示出3到10倍的提升。

The company is planning to expand to additional cell types and is actively seeking partners to advance the use of its liver cells for toxicity testing, disease modeling, and therapeutics..

公司计划扩展到更多的细胞类型，并正在积极寻找合作伙伴，以推进其肝细胞在毒性测试、疾病建模和治疗中的应用。

“At Stately Bio, we’re unlocking the power to decode cellular behaviors previously invisible to science,” said Frank Li, Founder and CEO of Stately Bio. “This seed funding allows us to scale our technology and transform the landscape of regenerative medicine—making cell therapies faster to develop, more affordable, and accessible to all.”.

“在Stately Bio，我们正在释放解码以前科学无法观察到的细胞行为的能力，”Stately Bio创始人兼首席执行官Frank Li表示。“这笔种子资金使我们能够扩展我们的技术，并改变再生医学的格局——使细胞疗法的开发更快速、更经济实惠，并且普及所有人。”

Stately Bio has validated its technology through multiple partnerships across different cell types and use cases. In a recent preclinical study with the New York Blood Center (NYBC), Stately Bio’s ML platform was able to identify specific subpopulations of stem cell-derived immune cells faster and more efficiently than gold-standard flow cytometry and immunofluorescence assays.

Stately Bio通过与不同细胞类型和应用场景的多个合作伙伴验证了其技术。在近期与纽约血液中心（NYBC）进行的一项临床前研究中，Stately Bio的机器学习平台能够比金标准的流式细胞术和免疫荧光检测更快、更高效地识别干细胞衍生免疫细胞的特定亚群。

This technical achievement earned the company the Top Scoring Start-Up (Enabler) Abstract Award at the upcoming ISCT 2025 Scientific Annual Meeting in New Orleans..

这项技术成就使该公司在即将于新奥尔良举行的ISCT 2025科学年会上荣获“最高评分初创企业（推动者）”摘要奖。

“It’s very exciting to see the community recognize the utility of the idea and impact of Stately Bio’s technology. This is a powerful new capability that fundamentally reshapes how one can approach cell therapy discovery and manufacturing. We are proud to work with Stately Bio on these important advancements,” said Larry Luchsinger, Ph.D., Chief Scientific Officer at NYBC..

“看到社会认可Stately Bio技术的理念和影响力，令人感到非常兴奋。这是一种强大的新能力，从根本上重塑了细胞治疗发现和制造的方式。我们很自豪能与Stately Bio合作，推动这些重要的进展，”纽约血液中心首席科学官拉里·卢克斯博士表示。

Stately Bio’s team brings together seasoned experts in machine learning, stem cell biology, and biomanufacturing. The company was founded by Frank Li, an AI specialist who previously led machine learning at Alphabet’s Calico Life Sciences. He’s joined by an interdisciplinary team who bring deep technical know-how and industry experience from MIT’s Broad Institute, Stanford’s Institute for Stem Cell Biology and Regenerative Medicine, Vertex Pharmaceuticals, and National Resilience..

Stately Bio的团队汇集了在机器学习、干细胞生物学和生物制造领域经验丰富的专家。该公司由李·弗兰克（Frank Li）创立，他是一位人工智能专家，曾领导Alphabet旗下Calico生命科学的机器学习工作。与他共同组建团队的是一支跨学科的专业队伍，他们带来了来自麻省理工学院博德研究所、斯坦福大学干细胞生物学与再生医学研究所、Vertex制药公司以及国家韧性组织的深厚技术知识和行业经验。

Companies interested in partnering with Stately Bio can learn more at https://statelybio.com.

有兴趣与 Stately Bio 合作的公司可以访问 https://statelybio.com 了解更多信息。

About Stately Bio

关于庄严生物

Stately Bio is a biotechnology company building machine learning for regenerative medicine. Founded in 2022 and headquartered in Palo Alto, Stately Bio has developed an industry-leading computational platform that enables rapid, real-time insights into cell identity, quality, and behavior based on live-cell imaging.

Stately Bio是一家致力于为再生医学构建机器学习的生物技术公司。公司成立于2022年，总部位于帕洛阿尔托，已开发出一个行业领先的计算平台，能够基于活细胞成像提供快速、实时的细胞身份、质量和行为洞察。

Stately Bio is harnessing its platform’s technological advantage to develop cell therapies and regenerative medicines for diseases of high unmet need. Learn more at https://statelybio.com..

Stately Bio 正在利用其平台的技术优势，开发针对高度未满足需求疾病的细胞疗法和再生医学。更多信息请访问 https://statelybio.com。